大规模的多组学识别了心力衰竭的药物标,减少并保留了喷射分数
Danielle Rasooly1,2, Claudia Giambartolomei3, Gina M Peloso4,5
1Million Veteran Program (MVP) Coordinating Center, Veterans Affairs Healthcare System, Boston, MA, USA. danielle.rasooly@va.gov.
Nature cardiovascular research
|February 6, 2025
概括
这项研究确定了心力衰竭的不同治疗点,包括减少喷射率 (HFrEF) 和保留喷射率 (HFpEF). 发现非重叠的目标突显了个性化HFrEF和HFpEF治疗的必要性.
科学领域:
- 遗传学和基因组学 遗传学和基因组学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 具有有限的治疗选择,需要对其亚型有更深入的了解.
- 独特的病理生理机制是减少喷射分数 (HFrEF) 的高压和保持喷射分数 (HFpEF) 的高压的基础.
研究的目的:
- 区分HFrEF和HFpEF的病理生理基础.
- 为了发现心力衰竭的亚型特定的治疗策略.
- 为了确定HFrEF和HFpEF的新药可用目标.
主要方法:
- 使用蛋白质组和转录组数据,采用孟德尔的随机化分析.
- 这项研究包括来自百万退伍军人计划的超过42万名参与者,在超过175,000名个人中进行复制.
- 创建了治疗标档案,评估了疗效,安全性,新性,可用性和作用机制.
主要成果:
- 确定了70个HFrEF和10个HFpEF目标,其中58个是新的.
- HFrEF和HFpEF的目标没有重叠,这支持了对亚型特定疗法的需求.
- 涉及HFrEF的关键途径包括无素蛋白酶系统,SUMOylation,炎症和线粒体代谢.
结论:
- 这些发现强调了开发HFrEF和HFpEF不同的治疗策略的必要性.
- IL6R,ADM和EDNRA被确定为潜在的HFrEF目标.
- 对于HFrEF和HFpEF,LPA是潜在的治疗标.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
01:22Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
01:26Heart Failure Drugs: Inotropic Agents
505
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
505